公开(公告)号：EP0636370B2

公开(公告)日：2004-01-02

申请号：EP94304144.2

申请日：1994-06-09

申请人： Euro-Celtique S.A.

发明人： Heafield, Joanne ,  Knott, Trevor John ,  Leslie, Stewart Thomas ,  Malkowska, Sandra Therese Antoinette ,  Miller, Ronald Brown ,  Prater, Derek Allan ,  Smith, Kevin John ,  Chasin, Mark ,  Goldenheim, Paul ,  Oshlack, Benjamin ,  Pedi, Frank, Jr. ,  Sackler, Richard ,  Kaiko, Robert

IPC分类号： A61K31/485 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K31/522 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2081 ,  A61K9/2095 ,  A61K9/2866 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5078 ,  A61K31/135 ,  A61K31/137 ,  A61K31/485

公开(公告)号：EP1348429A3

公开(公告)日：2003-11-26

申请号：EP03015267.2

申请日：1995-11-03

申请人： Euro-Celtique S.A.

发明人： Oshlack, Benjamin ,  Chasin, Mark ,  Huang, Hua-Pin ,  Sackler, David

IPC分类号： A61K9/16 ,  A61K9/20

CPC分类号： A61K9/1635 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2095 ,  Y10S514/951 ,  Y10S514/962

摘要： Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.

摘要翻译： 公开了生物可利用的持续释放口服阿片样物质止痛剂剂型，其包含通过熔体挤出技术制备的多个多颗粒。

公开(公告)号：EP1348429A2

公开(公告)日：2003-10-01

申请号：EP03015267.2

申请日：1995-11-03

申请人： Euro-Celtique S.A.

发明人： Oshlack, Benjamin ,  Chasin, Mark ,  Huang, Hua-Pin ,  Sackler, David

IPC分类号： A61K9/16 ,  A61K9/20

CPC分类号： A61K9/1635 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2095 ,  Y10S514/951 ,  Y10S514/962

摘要： Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.

摘要翻译： 公开了包含通过熔融挤出技术生产的多个多颗粒的生物可持续释放的口服阿片类镇痛剂型。 公开了包含通过熔体挤出技术生产的多个多颗粒的生物可持续释放的口服阿片类镇痛剂型。

公开(公告)号：EP1328273A2

公开(公告)日：2003-07-23

申请号：EP01988573.0

申请日：2001-10-23

申请人： Euro-Celtique, S.A.

发明人： TAVARES, Lino ,  SHEVCHUK, Ihor ,  ALFONSO, Mark ,  MARCENYAC, Geraldine ,  VALIA, Kirti, H.

IPC分类号： A61K31/4418 ,  A61K31/4422

CPC分类号： A61K9/7061 ,  A61K9/7069 ,  A61K31/4422

摘要： A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.

公开(公告)号：EP1272035A1

公开(公告)日：2003-01-08

申请号：EP01957138.9

申请日：2001-07-12

申请人： Euro-Celtique, S.A.

发明人： SIMON, David Lew

IPC分类号： A01N43/42

CPC分类号： A61K31/167 ,  A61K31/485 ,  A61K31/60 ,  A61K2300/00

摘要： A kappa opioid blocking agent is used for optimizing dopamine homeostasis during administration of opioid analgesics, for preventing mortal respiratory depression due to drug overdose, and for dissuading a human or animal from self-administering excessive amounts the opioid analgesic.

公开(公告)号：EP1265866A2

公开(公告)日：2002-12-18

申请号：EP01918558.6

申请日：2001-03-12

申请人： Euro-Celtique S.A. ,  Hogenkamp, Derk, J. ,  Nguyen, Phong ,  Shao, Bin

发明人： HOGENKAMP, Derk, J. ,  NGUYEN, Phong ,  SHAO, Bin

IPC分类号： C07D213/81 ,  C07D239/28 ,  C07D239/38 ,  C07D251/24 ,  C07D241/24 ,  C07D403/04 ,  A61K31/505 ,  A61P25/08

CPC分类号： C07D213/81 ,  C07D239/28 ,  C07D239/38 ,  C07D241/24 ,  C07D251/24 ,  C07D403/04

摘要： This invention relates aryl substituted pyridines, pyrimides, pyrazines and triazines of Formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A1, A2, A3, R1-R4, X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhytmics and for the treatment of prevention of diabetic neuropathy.

公开(公告)号：EP1258246A2

公开(公告)日：2002-11-20

申请号：EP02008249.1

申请日：1992-11-25

申请人： Euro-Celtique S.A.

发明人： Oshlack, Benjamin ,  Chasin, Mark ,  Minogue, John Joseph ,  Kaiko, Robert Francis

IPC分类号： A61K31/485 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/5015 ,  A61K31/485

摘要： A method for substantially reducing the range in daily dosages required to control pain in approximately 80% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hours) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients. The figure is a graph showing the mean plasma oxycodone concentration for a 10 mg controlled release oxycodone formulation prepared in accordance with the present invention and a study reference standard.

摘要翻译： 公开了一种用于大大减少约80％患者中控制疼痛所需的日剂量范围的方法，其中向患者施用具有约10至约40mg羟可待酮或其盐的口服固体控制释放剂量制剂。 该制剂提供给药后平均约2至约4.5小时约6至约60ng / ml的羟考酮的平均最大血药浓度，并且平均最小血浆浓度为约3至约30ng / ml，约10 经过稳态条件重复“q12h”（即每12小时）至14小时。 另一个实施方案涉及用于基本上减少在基本上所有患者中控制疼痛所需的日剂量范围的方法。 该图是显示根据本发明制备的10mg控释羟考酮制剂的平均血浆羟考酮浓度和研究参考标准的图。

公开(公告)号：EP1227798A1

公开(公告)日：2002-08-07

申请号：EP00976730.2

申请日：2000-10-30

申请人： Euro-Celtique S.A.

发明人： OSHLACK, Benjamin ,  HUANG, Hua-Pin ,  TONELLI, Alfred, P. ,  MASSELINK, John

IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/26 ,  A61K9/48 ,  A61K9/52 ,  A61K9/14

CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K9/0087 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/282 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4866 ,  A61K9/50 ,  A61K9/5026

摘要： A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

公开(公告)号：EP1210583A1

公开(公告)日：2002-06-05

申请号：EP00961420.7

申请日：2000-08-30

申请人： Euro-Celtique S.A.

发明人： PALERMO, Philip ,  BYNUM, Kevin, C. ,  POCREVA, John ,  PINE, Bud

IPC分类号： G01N21/63

CPC分类号： G01J3/433 ,  G01N21/05 ,  G01N21/33 ,  G01N21/359 ,  G01N21/65 ,  G01N21/8507 ,  G01N33/15 ,  G01N2013/006 ,  G01N2021/6484 ,  G01N2021/651 ,  G01N2021/8521 ,  G01N2021/8528

摘要： A detection system used for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a singular dissolution vessel or multiple dissolution vessels (60) containing a dissolution medium and a measuring device (50) for detecting the amount of drug released at a given time is provided.

公开(公告)号：EP1201233A1

公开(公告)日：2002-05-02

申请号：EP01308949.5

申请日：2001-10-22

申请人： Euro-Celtique S.A.

发明人： Leslie, Stewart Thomas

IPC分类号： A61K9/70 ,  A61K31/485

CPC分类号： A61K9/7023 ,  A61K31/485

摘要： A distressing substance is added to opioid analgesic compositions intended for percutaneous administration, in order to prevent drug abuse.

摘要翻译： 为了防止药物滥用，将一种令人痛心的物质加入到用于经皮给药的阿片类止痛组合物中。